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Abstract
Background: Lung cancer is a major cause of death worldwide. Gene promoter methylation is a major inactivation
mechanism of tumor-related genes, some of which can be served as a biomarker for early diagnosis and prognosis
evaluation of lung cancer.
Methods: We determined the promoter methylation of 6 genes using quantitative methylation-specific PCR (Q-
MSP) technique in 96 clinically well-characterized non-small cell lung cancer (NSCLC).
Results: Highly frequent promoter methylation was found in NSCLC. With 100% diagnostic specificity, high
sensitivity, ranging from 44.9 to 84.1%, was found for each of the 6 genes. Our data also showed that promoter
methylation was closely associated with histologic type. Most of genes were more frequently methylated in
squamous cell carcinomas (SCC) compared to adenocarcinomas (ADC). Moreover, promoter methylation
significantly increased the risk of pleural indentation in NSCLC.
Conclusion: Our findings provided evidences that multiple genes were aberrantly methylated in lung
tumorigenesis, and demonstrated the promoter methylation was closely associated with clinicopathologic
characteristics of NSCLC. More importantly, we first revealed promoter methylation may be served as a potentially
increased risk factor for pleural indentation of NSCLC patients.
Background
Lung cancer is a leading cause of cancer death world-
wide, accounting for 30% of all cancer-related deaths
[1]. The 5-year survival rate between 1996-2004 is 16%-
significantly lower than that of other major cancers [2].
Owing to the rapid industrialization and increase in the
smoking consumption in society, lung cancer presents
as the number one cancer type of threats in China [3].
Epidemiological evidence has documented that approxi-
mately 41.8 men and 19.3 women per 100,000 Chinese
individuals died of lung cancer in 2005 [4]. Lung cancer
is generally classified into two major histological cate-
gories, small cell lung cancer (SCLC) and non-small cell
lung cancer (NSCLC). The latter accounts for approxi-
mately 85% of lung cancer [2]. Approximately 25-33% of
NSCLC patients present with stage I or II disease, which
permits surgical resection with curative intent. However,
despite surgery, approximately 30-40% of patients with
NSCLC who have discrete lesions and histologically
negative lymph nodes die of recurrent disease [5].
Despite the fact that the cause of most lung cancer is
well know, the disease has proven difficult to diagnosis
early and treat successfully, reflecting limited advances
in our understanding of the molecular mechanisms
underlying lung carcinogenesis and individual suscept-
ibility to lung cancer.
In addition to genetic factors [6-8], epigenetic altera-
tions play an important role in lung cancer development
and result in changes in gene function [9]. DNA methy-
lation is an epigenetic event whose pattern is altered fre-
quently in a wide variety of human cancers, including
promoter-specific hypermethylation as well as genome-
wide hypomethylation [10,11]. Gene promoter hyper-
methylation is among the earliest and most common
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leads to gene silencing and inactivation [12,13].
In the present study, we sought to identify DNA
methylation profiles in NSCLC and their association
with known or suspected cancer risk factors. For this,
we used quantitative methylation-specific PCR (Q-MSP)
to evaluate promoter methyla t i o no fap a n e lo fc a n c e r -
associated genes in a large cohort of clinically well-char-
acterized NSCLC samples, including calcitonin-related
polypeptide alpha (CALCA), E-cadherin (CDH1), death-
associated protein kinase 1 (DAPK1), iroquois homeo-
box 1 (IRX2), TIMP metallopeptidase inhibitor 3
(TIMP3), and paired box 6 (PAX6). These genes were
potentially important in NSCLC, some of which have
been assessed by others but some of which have not
been evaluated previously.
Methods
Study subjects and DNA isolation
Ninety-six tumor samples and 15 nonmalignant lung
samples were obtained from NSCLC patients who
underwent curative resection at the First Affiliated Hos-
pital of China Medical University, with approval by the
institutional review board of the Hospital. None of these
patients received chemotherapy and radiotherapy before
the surgery. Informed consent was obtained from each
patient before the surgery. All of the samples were his-
tologically examined by a pathologist at Department of
Pathology of the Hospital to identify the type and other
clinical characteristics of the tumors. The clinical files of
these patients are shown in Table 1. Samples were pre-
pared and genomic DNA was isolated from paraffin-
embedded samples as previously described [14]. Briefly,
after a treatment for overnight at room temperature
with xylene to remove pareffin, tissues were digested
with 1% sodium dodecyl sulfate (SDS) and 0.5 mg/ml
proteinase K at 48°C for 48 h, with addition of several
spiking aliquots of concentrated proteinase K to faciliate
digestion. DNA was subsequently isolated using stan-
dard phenol/chloroform protocol, and was dissolved in
distilled water and stored at -80°C until use.
Sodium bisulfite treatment
DNA from the primary tumors and nonmalignant lung
samples was subjected to bisulfite treatment as
described previously [14]. Briefly, a final volume of 20 μl
of H2Oc o n t a i n i n g1 - 2μgg e n o m i cD N A ,1 0μg salmon
sperm DNA, and 0.3M NaOH was incubated at 50°C for
20 min to denature the DNA. The mixture was then
incubated for 2-3 h at 70°C in 500 μlo faf r e s h l yp r e -
pared solution containing 3 M sodium bisulfite (Sigma,
Saint Louis, MO), 10 mM hydroquinone (Sigma, Saint
Louis, MO). Subsequently, the DNA was recovered by a
Wizard DNA Clean-Up System (Promega Corp.,
Madison, WI) following the instructions of the manu-
facturer, followed by ethanol precipitation, and resus-
pension in 30 μlo fd e i o n i z e dH 2O. After bisulfite
processing, all unmethylated cytosine residues converted
to uracil, whereas the methylated cytosine residues
remained unchanged. Bisulfited-modified DNA samples
were stored at -80°C until use.
Quantitative methylation-specific PCR (Q-MSP) analysis
After sodium bisulfite conversion, the methylation ana-
lysis was performed by the fluorescence-based quantita-
tive PCR assay as described previously [14]. Briefly, the
Q-MSP amplification was carried out in triplicate for
each samples in a final reaction mixture of 20 μlc o n -
taining 3 μl bisulfite-treated DNA, 600 nM each primer,
Table 1 Clinicopathologic characteristics of NSCLC cases
Characteristics No. of patients (%)
Gender
Male 66 (69)
Female 30 (31)
Age (mean years ± S.D.) 58.9 ± 9.2
≤ 60 56 (58)
> 60 40 (42)
Smoking history (pack-years)
0 30 (31)
1-39 35 (37)
≥ 40 31 (32)
Tumor size (mean cm ± S.D.) 3.9 ± 1.7
1-3 37 (38)
3-5 44 (46)
> 5 15 (16)
Histologic type
Adenocarcinoma (ADC) 30 (31)
Brochoalveplar cell (BAC) 6 (6)
Adenocarcinoma (non-BAC) 24 (25)
Squamous (SCC) 66 (69)
Histologic stage
I 54 (56)
II 32 (34)
III 10 (10)
Lymph node metastasis
No 70 (73)
Yes 26 (27)
Pleural indentation
No 75 (78)
Yes 21 (22)
Invasion or Adhesion
No 65 (68)
Yes 31 (32)
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Page 2 of 9200 nM TaqMan probe, 5.5 mM MgCl2, 1 U platinum
Taq polymerase, 200 μM each of deoxyguanosine tri-
phosphate, and 2% Rox reference. After an initial dena-
turation step at 95°C for 2 min, 40 cylces of 15 sec at
95°C and 60 sec at 60°C for annealing and extension
were run using an ABI 7500 Fast Real-Time PCR Sys-
tem (Foster City, CA). Normal leukocyte DNA was
methylated in vitro with Sss I methylase (New Engliand
Biolabs, Beverly, MA) to generate completely methylated
DNA as a positive control. Each plate contained tripli-
cate samples and multiple water blanks, as well as serial
dilutions of positive methylated control to construct the
standard curve. The internal reference gene b-actin was
used to normalize the amount of input DNA. The pri-
m e r sa n dT a q M a np r o b e su s e di nt h ep r e s e n ts t u d y
were presented in Table 2. The relative degree of
methylation of each sample was calculated using the
method described previously [15].
Statistical analysis
Promoter methylation was considered present if the
ratio was above a certain cut-off value. The relative
level of methylation varied significantly among the 6
genes and therefore cut-off points were studied for
each gene individually. To set up cut-off value for each
gene for detection of NSCLC, we used the Medcalc
Software (MedCalc Software bvba, Belgium) to con-
struct receiver operating characteristic (ROC) curves.
T h ea r e au n d e rt h ec u r v eo fR O Cc u r v ei sam e a s u r e
of the ability of a continuous marker to accurately clas-
sify tumor and non-tumor tissue. Such a curve is a plot
of sensitivity vs. 1 minus specificity values associated
with all dichotomous markers that can be formed by
varying the value threshold (or cut-off value) used to
designate a marker “positive”. Factors associated with
patients and tumor characteristics were assessed uni-
variately with chi-square tests for trend and logistic
regression. In the final analysis, multivariable adjust-
ments were made to adjust for the potentially con-
founding effects of smoking history, histologic type,
lymph node metastasis, and pleural indentation. P <
0.05 was considered to be statistically significant. All
statistical analyses were performed using the SPSS sta-
tistical package (11.5, Chicago, IL, USA).
Results
Demographics
In the present study, we chose genes which were poten-
tially important in NSCLC and determined the promoter
methylation of these 6 genes using Q-MSP assay in 96
well-characterized NSCLC patients. As shown in Table
1 the mean age of the 96 NSCLC cases was 58.9 years.
Males were more than females (69% vs. 31%). Sixty-nine
percent of patients reported a history of smoking, with
32% reporting at least 40 life-time pack-years of smok-
ing. Ninety percent of NSCLC cases had surgical stage
I or II disease and 84% had tumors < 5 cm. By histology,
31% of tumors were adenocarcinomas (ADC), including
6% bronchioloalveolar carcinomas (BAC) and 25% non-
BAC adenocarcinomas, and 69% were squamous cell
carcinomas (SCC). The cases with lymph node metasta-
sis, pleural indentation and invasion or adhesion were in
26/96 (27%), 21/96 (22%), and 31/96 (32%), respectively.
Frequent promoter methylation in NSCLC
We examined promoter methylation of CALCA, CDH1,
DAPK1, IRX2, TIMP3,a n dPAX6 using Q-MSP in a
cohort of 96 NSCLC. As shown in Figure 1, the overall
methylation level of each gene was higher in tumor tis-
sues than in nonmalignant lung tissues. Among the
6 genes examined, statistical significances were observed
in CALCA (P < 0.01), CDH1 (P < 0.01), and PAX6 (P <
0.001). We set up appropriate cut-off values to distin-
guish NSCLC from nonmalignant lung tissues, and
determine diagnostic sensitivity and specificity. As
shown in Figure 2, with 100% diagnostic specificity for
each of the 6 genes, the sensitivity of CALCA, CDH1,
DAPK1, IRX2, TIMP3,a n dPAX6 was 69.2%, 45.8%,
84.1%, 52.3%, 44.9%, and 75.7%, respectively.
Association of promoter methylaton with
clinicopathological charactristics of NSCLC
Among all clinicopathologic characteristics, methylation
levels varied substantially by histologic type (Table 3).
Table 2 Quantitative methylation-specific PCR primer and TaqMan probe sequences used in the present study
Genes Forward primer sequence (5’®3’) Probe sequence (5’®3’) Reverse primer sequence (5’®3’)
CALCA GTTTTGGAAGTATGAGGGTGACG 6FAM-ATTCCGCCAATACACAACAACCAATAAACG-TAMRA TTCCCGCCGCTATAAATCG
CDH1 AATTTTAGGTTAGAGGGTTATCGCGT 6FAM-CGCCCACCCGACCTCGCAT-TAMRA TCCCCAAAACGAAACTAACGAC
DAPK1 GGATAGTCGGATCGAGTTAACGTC 6FAM-TTCGGTAATTCGTAGCGGTAGGGTTTGG-TAMRA CCCTCCCAAACGCCGA
IRX2 GCGGGTCGTTTAGGTTAGTATTCG 6FAM-CCCTCCATCCACGCCCGACCGAAA-TAMRA CGCCGAACAACGAACAAAACG
TIMP3 GCGTCGGAGGTTAAGGTTGTT 6FAM-AACTCGCTCGCCCGCCGAA-TAMRA CTCTCCAAAATTACCGTACGCG
PAX6 ATATAGGACGGCGGTTTAGGTTG 6FAM-CCCAAAATCCGACCGACTCCAACCCCTA-TAMRA TTCCGACCGAACGAAAACCTAC
b-Actin TGGTGATGGAGGAGGTTTAGTAAGT 6FAM-ACCACCACCCAACACACAATAACAAACACA-TAMRA AACCAATAAAACCTACTCCTCCCTTAA
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Page 3 of 9Figure 1 Distribution patterns of promoter methylation of the 6 genes in NSCLC. Q-MSP was performed as described in Materials and
Methods. The relative methylation level (on Y axis) is represented by ratios of candidate gene/b-actin × 1000, except for PAX6/b-actin × 100. Horizonal
lines indicate a 95% normal confidence interval for the sample mean. T, tumor tissues; N, nonmalignant lung tissues. **, P < 0.01; ***, P <0 . 0 0 1 .
Figure 2 Receiver operating characteristic (ROC) curves for the 6 genes in NSCLC. All tumor and nonmalignant lung tissues for which
there was complete DNA methylation data were used for the analyses. The ROC curves plot sensitivity vs. 100-specificity. The determined cut-off
values for CALCA, CDH1, DAPK1, IRX2, TIMP3, and PAX6 were 45.7, 29.0, 0, 58.8, 48.2, and 13.0, respectively.
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Page 4 of 9Methylation level of most of genes was higher in SCC
than in ADC, particularly in CDH1 gene (P <0 . 0 5 )
(Table 3). There was a significant difference in the
methylation level of DAPK1 gene between lymph node
metastasis group and nonmetastasis group (40.3 ± 100.5
in the former vs. 12.3 ± 18.5 in the latter, P <0 . 0 5 )
(Table 3). The methylation level of CALCA gene was
significant higher in the patients with invasion or adhe-
sion compared with patients without invasion or adhe-
sion (174.5 ± 160 vs. 115.1 ± 122.5, P < 0.05) (Table 3).
The methylation level of CALCA gene was found to be
significantly associated with smoking history (155.2 ±
150.2 in smokers vs.8 9 . 6±9 2 . 7i nn o n - s m o k e r s ,P <
0.05) (Table 3). Our data showed that the methylation
level of most of genes was not associated with quantity
of cigarette smoking (Pack-years) (Additional file 1). Of
note, there was a significant difference in the methyla-
tion level of PAX6 gene between patients with age > 60
years and ≤ 60 years (28.6 ± 16.2 in the former vs.2 0 . 2
± 12.4 in the latter, P < 0.05). In addition, the methyla-
tion level of CALCA gene was also found to be signifi-
cantly associated with tumor stage (217.7 ± 186.7 in
patients with histoligical satge ≥ III vs. 125 ± 129 in
patients with histological stage < III, P < 0.05) (Addi-
tional file 1). The methylation level of several genes
was associated with increased tumor size, including
CALCA, DAPK1, IRX2,a n dTIMP3 genes, although
these associations did not reach statistical difference
(Additional file 1).
In univariate analyses, the promoter methylation of
most of genes was more frequent in SCC compared to
ADC, particularly in CDH1(OR = 2.63, 95% CI = 1.05-
6.60), DAPK1 (OR = 6.64, 95% CI = 1.85-23.8), IRX2
(OR = 2.89, 95% CI = 1.17-7.13), and TIMP3 (OR =
2.51, 95% CI = 1.01-6.21) (Table 4). In addition, methy-
lation of CALCA (OR = 2.13, 95% CI = 1.01-4.47) and
TIMP3 (OR = 1.88, 95% CI = 1.01-3.49) was signifi-
cantly associated with histologic stage (Table 4). How-
ever, there was not significant association between
promoter methylation and other clinocopathologic char-
acteristics, including gender, age, smoking history, quan-
tity of cigarette smoking, tumor size, lymph node
metastasis, pleural indentation, and invasion or adhesion
(Table 4). In order to assess the independent associa-
tions between promoter methylation and smoking his-
tory, histologic type, lymph node metastasis, and pleural
indentation, we conducted multiple multivariable logistic
regressions (Table 5). In multivariable analyses adjusting
for potential false discovery rate associated with multiple
comparisons (6 different models), methylation of most
of genes ramained associated with histologic type. The
promoter methylation of CDH1(OR = 6.77, 95% CI =
1.71-26.8), DAPK1 (OR = 10.7, 95% CI = 2.16-52.6),
IRX2 (OR = 6.38, 95% CI = 1.17-23.0), and TIMP3
(OR = 3.37, 95% CI = 1.03-11.0) genes was significant
more likely in SCC compared to ADC (Table 5). However,
after adjustment for smoking history, histologic type, and
lymph node metastasis, the promoter methylaton of each
Table 3 Association of the level of promoter methylation with clinicopathologic charactristics of NSCLC
Genes
Gender (n = 96) Histologic type (n = 96) Smoking history (n = 96)
Female Male P SCC ADC P YN P
(n = 30) (n = 66) (n = 66) (n = 30) (n = 66) (n = 30)
CALCA 145.0 ± 149.6 112.1 ± 106.5 0.28 152.1 ± 152.1 96.4 ± 90.6 0.07 155.2 ± 150.2 89.6 ± 92.7 0.03*
CDH1 33.1 ± 18.7 31.5 ± 21.2 0.71 35.4 ± 19.2 26.3 ± 18.6 0.03* 32.2 ± 18.7 33.4 ± 21.3 0.77
DAPK1 18.5 ± 59.6 23 ± 45.2 0.71 26.2 ± 65.8 5.9 ± 7.6 0.09 17.4 ± 59.6 25.4 ± 45.2 0.52
IRX2 96.4 ± 131.5 63.9 ± 34.8 0.19 92.3 ± 115.7 72.9 ± 103.6 0.43 95.3 ± 132.1 66.3 ± 36.1 0.24
TIMP3 60.5 ± 72.8 50.9 ± 39.1 0.50 64.9 ± 71.7 41.3 ± 39.8 0.09 61.5 ± 72.8 48.8 ± 38.9 0.37
PAX6 23.4 ± 15.1 24.2 ± 13.8 0.78 24.0 ± 15.5 23.1 ± 12.8 0.79 23.9 ± 15.6 23.3 ± 12.6 0.85
Genes Lymph node metastasis (n = 96) Pleural indentation (n = 96) Invasion or Adhesion (n = 96)
YN P YN P YN P
(n = 26) (n = 70) (n = 21) (n = 75) (n = 31) (n = 65)
CALCA 175.7 ± 175.1 119.5 ± 119.1 0.08 129.9 ± 132.5 136 ± 140.2 0.86 174.5 ± 160 115.1 ± 122.5 0.048*
CDH1 31.0 ± 13.9 33.1 ± 21.2 0.64 35.3 ± 21.2 31.8 ± 18.9 0.47 30.7 ± 16.6 33.5 ± 20.7 0.52
DAPK1 40.3 ± 100.5 12.3 ± 18.5 0.03* 12.4 ± 11.9 21.9 ± 62.3 0.49 10.9 ± 10.6 24.2 ± 66.6 0.27
IRX2 42.7 ± 51 91.2 ± 127.2 0.47 73.1 ± 38.4 89.9 ± 124.9 0.54 71.8 ± 48.3 93.1 ± 131.6 0.38
TIMP3 69.3 ± 91 53.2 ± 51 0.28 53.9 ± 42.9 58.6 ± 69.2 0.77 52.7 ± 53.1 59.8 ± 69.1 0.61
PAX6 23.2 ± 14.2 23.9 ± 14.9 0.83 25.2 ± 13.9 23.3 ± 14.9 0.59 25.8 ± 15.7 22.7 ± 14.1 0.32
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tion compared with without pleural indentation (Table 5),
particularly in CDH1(OR = 5.27, 95% CI = 1.27-21.9),
DAPK1 (OR = 6.98, 95% CI = 1.06-45.8), and IRX2 (OR =
3.89, 95% CI = 1.01-15.0) genes, suggesting that promoter
methylation of these genes may be a potential risk of
pleural indentation in NSCLC.
Discussion
We assessed the promoter methylation of the 6 genes in
a large cohort of well-characterized NSCLC subjects
using Q-MSP technique in the present study, including
CALCA, CDH1, DAPK1, IRX2, TIMP3,a n dPAX6.
CALCA i sk n o w nt oe n c o d eap e p t i d eh o r m o n et h a t
plays a role in maintenance of calcium levels in blood
serum and T-and B-cell regulation in certain malignan-
cies, which is frequently methylated in multiple types
of cancer [16,17]. CDH1 is a classical cadherin from
the cadherin superfamily, which encodes a calcium
dependent cell-cell adhesion protein. Epigenetic inacti-
vation of CDH1 is thought to contribute to progression
in cancer by increasing proliferation, invasion, and/or
metastasis [18]. DAPK1 encodes a structurally unique
calcium/calmodulin-dependent serine/threonine kinase
which acts as a positive regulator of apoptosis. It is fre-
quently methylated in human cancers as a tumor sup-
p r e s s o rg e n e[ 1 9 ] .I R X 2i sam e m b e ro ft h eI r o q u o i s
homeobox transcription factor family, which is involved
in developmental pattern formation in multiple organs
such as the brain and heart [20]. It is highly specific for
tumor-associated methylation, and little or no methyla-
tion is found in nonmalignant lung tissue [21]. TIMP3
is an angiogenesis inhibitor, and its epigenetic inactiva-
tion is associated with neovascularization and invasion
in human malignancy [22]. PAX6, a transcription factor,
has currently been suggested to function as a tumor
suppressor in glioblastoma and to act as an early differ-
entitation marker for neuroendocrine cells [23], which is
Table 4 Promoter methylation in NSCLC-univariate associations with clinicopathologic characteristics (OR
† and 95% CI)
Genes Male vs. Female Age (per 10 years) Smoking history Pack-years
1 SCC vs. ADC
CALCA 0.73 (0.28-1.90) 0.94 (0.58-1.52) 1.43 (0.57-3.57) 0.88 (0.51-1.51) 2.21 (0.89-5.47)
CDH1 2.13 (0.86-5.22) 0.83 (0.53-1.30) 1.41 (0.59-3.39) 0.91 (0.55-1.50) 2.63 (1.05-6.60)*
DAPK1 1.45 (0.43-4.87) 1.16 (0.60-2.24) 2.11 (0.64-6.92) 1.83 (0.84-3.98) 6.64 (1.85-23.8)*
IRX2 1.29 (0.54-3.06) 0.76 (0.48-1.19) 1.06 (0.45-2.52) 0.91 (0.55-1.50) 2.89 (1.17-7.13)*
TIMP3 1.09 (0.46-2.60) 1.09 (0.70-1.71) 1.09 (0.46-2.60) 1.27 (0.76-2.11) 2.51 (1.01-6.21)*
PAX6 1.04 (0.37-2.88) 1.19 (0.70-2.03) 0.78 (0.27-2.25) 0.93 (0.51-1.69) 1.04 (0.37-2.88)
Genes Tumor size
2 Lymph node metastasis Pleural indentation Invasion or Adhesion Histologic stage
3
CALCA 1.01 (0.55-1.88) 1.74 (0.62-4.91) 1.18 (0.41-3.41) 2.44 (0.88-6.79) 2.13 (1.01-4.47)*
CDH1 1.20 (0.67-2.13) 1.02 (0.41-2.51) 1.79 (0.67-4.76) 0.96 (0.41-2.27) 1.11 (0.62-2.02)
DAPK1 1.81 (0.72-4.54) 5.17 (0.64-41.95) 1.63 (0.33-8.02) 1.70 (0.43-6.67) 1.24 (0.50-3.08)
IRX2 1.57 (0.88-2.83) 1.17 (0.47-2.88) 1.37 (0.52-3.63) 0.86 (0.36-2.01) 1.14 (0.63-2.07)
TIMP3 1.67 (0.92-3.01) 2.05 (0.82-5.10) 1.16 (0.44-3.05) 0.69 (0.29-1.66) 1.88 (1.01-3.49)*
PAX6 0.78 (0.40-1.54) 0.74 (0.26-2.09) 2.04 (0.54-7.69) 1.84 (0.61-5.56) 1.76 (0.79-3.93)
† OR: odds ratio with 95% confidence interval.
1 Pack-years (0; > 0 and < 40; ≥ 40).
2 Tumor size (> 1 and ≤3; > 3 and ≤5; > 5).
3 Histologic stage (I; II; III).
* Significant at P < 0.05.
Table 5 Promoter methylation in NSCLC-multivariable models assessing smoking history, histologic type, lymph node
metastasis, and pleural indentation (OR
† and 95% CI)
Genes Smoking history SCC vs. ADC Lymph node metastasis Pleural indentation
CALCA 1.07 (0.40-2.88) 2.66 (0.85-8.32) 1.43 (0.46-4.41) 2.19 (0.61-7.79)
CDH1 0.98 (0.37-2.58) 6.77 (1.71-26.8)* 0.78 (0.29-2.13) 5.27 (1.27-21.9)*
DAPK1 0.83 (0.19-3.73) 10.7 (2.16-52.6)* 3.07 (0.32-29.4) 6.98 (1.06-45.8)*
IRX2 0.69 (0.26-1.83) 6.38 (1.77-23.0)* 0.85 (0.31-2.33) 3.89 (1.01-15.0)*
TIMP3 0.78 (0.30-2.02) 3.37 (1.03-11.0)* 1.75 (0.65-4.75) 2.66 (0.77-9.16)
PAX6 0.67 (0.21-2.08) 1.82 (0.50-6.57) 0.77 (0.25-2.38) 2.66 (0.58-12.3)
† OR: odds ratio with 95% confidence interval, adjusted for multiple comparisions.
* Significant at P < 0.05.
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larly, our findings also showed that 3 of 6 genes had sig-
nificantly higher methylation level in tumor tissues than
nonmalignant lung tissues, including CALCA, CDH1,
and PAX6 genes. Importantly, with 100% diagnostic spe-
cificity, excellent sensitivity, ranging from 44.9 to 84.1%,
was found for each of the 6 genes. The high specificity
and frequency of these methylation markers make them
excellent candidates for future applications developed
for early diagnosis and prognosis evaluation of lung
cancer.
Given smoking plays the central role in lung cancer
development, it is somewhat surprising that we did not
find significant association between promoter methyla-
tion of most genes and smoking history, in agreement
with most studies [25-28]. However, several previous
studies have reported aberrant DNA methylation of
tumor-related genes was associated with tobacco smok-
ing [29-32]. It is possible that lung cancer as a result of
tobacco smoking is a complex disease with many unique
genetic and epigenetic features. Better understanding of
the molecular mechanisms underlying this disease
would undoubtedly improve the outcomes of patients
with smoking-associated lung cancer.
Our findings of substantial differences in promoter
methylation depending on histologic typing of NSCLC
have been reported to some degree in the literatures.
Unlike what observed in the present study, a number
of others have noted that adenomatous polyposis
coli (APC), cyclin D2 (CCND2), potassium voltage-
gated channel, subfamily H( e a g - r e l a t e d ) ,m e m b e r5
(KCNH5), and runt-related transcription factor 2
(RUNX2) genes were significantly more frequently in
ADC compared to SCC [33-36]. Similar to the present
study, although no statistical significance was observed,
promoter methylation of DAPK1 gene was detected
with higher frequency in SCC compared to ADC [36].
Conversely, there was not significant difference in pro-
moter methylation of CDH1 gene between SCC and
ADC in this literature [36]. Anyway, we believe that our
findings that promoter methylation of several genes is
more frequent in SCC compared to ADC, particularly
IRX2 gene, are new to the literature. Moreover, methy-
lation level of DAPK1 and CALCA genes was signifi-
cantly associated with lymph node metastasis and
invasion/adhesion, suggesting that methylation degree
of these genes might contribute to oncologic outcomes
of NSCLC patients.
A very recent study showed that a number of impor-
tant differences in frequency of promoter methylation in
females compared to males, suggesting that promoter
methylation is associated with gender [36]. However,
these substantial differences have not been consistently
noted in the previous literatures [35,37-39]. Similarly,
promoter methylation was also not significantly asso-
ciated with gender in the present study. It is possible
that the differences in the promoter methylation asso-
ciated with gender may be related to the geographical or
cultural differences in carcinogen exposures, including
cigarette smoking, dietary factors, occupational and
environmental chemical exposure [40-42]. The discre-
pant results might also have been due to genetic differ-
ences of the study populations. A previous study
indicated that patients harboring functional polymorphic
variants of glutathione S-transferase pi 1 (GSTP1)h a da
higher risk of promoter hypermethylation of O-6-
methylguanine-DNA methyltransferase (MGMT)g e n e
[43], suggesting that functional variants in the genes
involved in the folate metabolism, DNA methylation,
carcinogen metabolosim and the repair of methylation
may play an important role in the susceptibility to pro-
moter methylation. However, it is possible that these
differences are attributable to chance as a result of the
relatively small number of the study subjects examined.
Therefore, further study with more subjects will be
needed.
Interestingly, multivariable analyses revealed that the
promoter methylation of a number of genes had signfi-
cant higher frequency in patients with pleural indenta-
tion compared with without pleural indentation,
suggesting that promoter methylation may be a poten-
tially increased risk for pleural indentation of NSCLC
patients. Pleural indentation is a well-known imaging
sign on chest computed tomography (CT) that suggests
a possible pleural invasion by peripheral NSCLC, parti-
cularly ADC [44,45]. A previous study showed that
pleural involvement was significantly correlated with a
poor prognosis in NSCLC, suggesting that pleural invol-
vement may be one of most important factors to affect
on the prognosis of NSCLC [46]. Although the degree
of pleural invasion is clinically important, the accurate
preoperative evaluation is sometimes difficult. CT and
magnetic resonance imaging (MRI) are usually used in
the evaluation of tumor extent, and diagnosis of chest
wall invasion, pleural dissemination and pleural effusion
can be easily made preooperatively by this way [47].
However, pleural dissemination and/or pleural effusion,
which were not documented preoperatively, were some-
times revealed during operation. In addition, the accru-
ate visceral pleural invasion can not be made with
preoperative CT or MRI. In the present study, our find-
ings suggested that promoter methylation of certain
genes can increase the risk of pleural indentation in
NSCLC. DNA methylation is the earliest and most fre-
quent molecular events in human tumorigenesis. Detec-
tion of aberrant methylation using some high-senstive
approaches can be thus used to predict and evaluate the
pleural invovlement in NSCLC.
Ji et al. Diagnostic Pathology 2011, 6:48
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In summary, in the present study, we found a panel of
methylated genes that differentiate tumor tissues from
nonmalignant lung tissues, which was strongly asso-
ciated with clinicopathologic characteristics of NSCLC.
Importantly, our data first revealed that promoter
methylation may be a potentially increased risk factor
for pleural indentation of NSCLC patients.
Additional material
Additional file 1: Table S1. Association of the level of promoter
methylation with age, pack-years, tumor size and histoligic stage in
NSCLC
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